Toremifene

Active ingredient: Toremifene Citrate

In short: Toremifene citrate tablets are estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.

Forms & strengthsTablet is 60 mg, white to off white colored, round shaped, uncoated tablets, debossed with “MT” on one side and plain on other side and free from physical defects.
LabelNovadoz Pharmaceuticals LLC
Label updatedSep 25, 2025

What is Toremifene used for?

Toremifene citrate tablets are estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.

âš  Boxed warning (FDA's strongest warning)

Toremifene citrate has been shown to prolong the QTc interval in a dose- and concentration-related manner

.

Prolongation of the QT interval can result in a type of ventricular tachycardia called Torsade de pointes, which may result in syncope, seizure, and/or death. Toremifene should not be prescribed to patients with congenital/acquired QT prolongation, uncorrected hypokalemia or uncorrected hypomagnesemia. Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided

.

Toremifene dosage

The dosage of toremifene citrate tablets are 60 mg, once daily, orally. Treatment is generally continued until disease progression is observed.

How to take Toremifene — instructions & advice from the label

Vaginal bleeding has been reported in patients using toremifene citrate. Patients should be informed about this and instructed to contact their physician if such bleeding or other gynecological symptoms (changes in vaginal discharge, pelvic pain or pressure) occur. Patients should have a gynecological examination prior to initiation of therapy and at regular intervals while on therapy. Liver disorders including transaminits grade 3 and 4, hyperbilirubinemia with jaundice have been reported in patients using toremifene citrate. Patients should have liver function tests performed periodically while on therapy. Toremifene citrate may harm the fetus and increase the risk for pregnancy loss .

Premenopausal women using toremifene citrate should use nonhormonal contraception during treatment and should be apprised of the potential hazard to the fetus should pregnancy occur .

Patients with bone metastases should be informed about the typical signs and symptoms of hypercalcemia and instructed to contact their physician for further assessment if such signs or symptoms occur. …

Warnings & precautions

Do not take this medicine if: Toremifene citrate is contraindicated in patients with known hypersensitivity to the drug.

Toremifene should not be prescribed to patients with congenital/acquired QT prolongation (long QT syndrome), uncorrected hypokalemia, or uncorrected hypomagnesemia.

Toremifene has been shown to prolong the QTc interval in a dose- and concentration-related manner

.

Prolongation of the QT interval can result in a type of ventricular tachycardia called Torsade de pointes, which may result in syncope, seizure, and/or death. Toremifene should be avoided in patients with long QT syndrome. Caution should be exercised in patients with congestive heart failure, hepatic impairment and electrolyte abnormalities. Hypokalemia or hypomagnesemia must be corrected prior to initiating toremifene and these electrolytes should be monitored periodically during therapy. Drugs that prolong the QT interval should be avoided. In patients at increased risk, electrocardiograms (ECGs) should be obtained at baseline and as clinically indicated .

Hepatotoxicity, both increases in the serum concentration for grade 3 and 4 transaminitis and hyperbilirubinemia, including jaundice, hepatitis, and non-alcoholic fatty liver disease, have also been reported in clinical trials and postmarketing with toremifene citrate. Liver function tests should be performed periodically.

As with other antiestrogens, hypercalcemia and tumor flare have been reported in some breast cancer patients with bone metastases during the first weeks of treatment with toremifene citrate. Tumor flare is a syndrome of diffuse musculoskeletal pain and erythema with increased size of tumor lesions that later regress. It is often accompanied by hypercalcemia. Tumor flare does not imply failure of treatment or represent tumor progression. …

Toremifene side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse drug reactions are principally due to the antiestrogenic actions of toremifene citrate and typically occur at the beginning of treatment. The incidences of the following eight clinical toxicities were prospectively assessed in the North American Study. The incidence reflects the toxicities that were considered by the investigator to be drug related or possibly drug related.

North American Study

FAR60 | TAM20

n = 221 | n = 215

Hot Flashes | 35% | 30%

Sweating | 20% | 17%

Nausea | 14% | 15%

Vaginal Discharge | 13% | 16%

Dizziness | 9% | 7%

Edema | 5% | 5%

Vomiting | 4% | 2%

Vaginal Bleeding | 2% | 4%

Approximately 1% of patients receiving toremifene citrate (n = 592) in the three controlled studies discontinued treatment as a result of adverse reactions (nausea and vomiting, fatigue, thrombophlebitis, depression, lethargy, anorexia, ischemic attack, arthritis, pulmonary embolism, and myocardial infarction). Serious adverse reactions occurring in at least 1% of patients receiving toremifene citrate in the three major trials are listed in the table below. Three prospective, randomized, controlled clinical studies (North American, Eastern European, and Nordic) were conducted. …

Drug interactions

Drugs that decrease renal calcium excretion, e.g., thiazide diuretics, may increase the risk of hypercalcemia in patients receiving toremifene citrate.

The administration of toremifene citrate with agents that have demonstrated QT prolongation as one of their pharmacodynamic effects should be avoided. Should treatment with any of these agents be required, it is recommended that therapy with toremifene citrate be interrupted. If interruption of treatment with toremifene citrate is not possible, patients who require treatment with a drug that prolongs QT should be closely monitored for prolongation of the QT interval. Agents generally accepted to prolong QT interval include Class 1A (e.g., quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). In patients at increased risk, electrocardiograms (ECGs) should be obtained and patients monitored as clinically indicated . …

About this medicine

Toremifene citrate tablets for oral administration each contain 88.5 mg of toremifene citrate, which is equivalent to 60 mg toremifene. Toremifene citrate tablets are estrogen agonist/antagonist. The chemical name of toremifene is: 2-{p-[(Z)-4-chloro-1,2-­diphenyl-1-butenyl]phenoxy}-N,N-dimethylethylamine citrate(1:1).The structural formula is:

and the molecular formula is C26H28ClNO . C6H8O7. The molecular weight of toremifene citrate is 598.10. The pKa is 7.76. Freely soluble in dimethyl sulphoxide, sparingly soluble in methanol and insoluble in water. Toremifene citrate tablets are available only as tablets for oral administration. Inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone K 30, and sodium starch glycolate.

How it works: Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e897546b-4136-4cb5-a262-d94cf3fa3298. Read the full official label on DailyMed.

Related medicines

Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone